KRAS/NRAS
EstablishedRAS mutation status determines anti-EGFR therapy eligibility in colorectal cancer; KRAS G12C now has its own targeted drug class.
KRAS and NRAS are genes that, when mutated, drive many cancers and also block a certain class of colon cancer drugs from working. A specific type of KRAS mutation now has its own targeted pill treatments, approved as recently as 2024 and 2025 — a genuine breakthrough after this gene was considered impossible to target directly for decades.
KRAS and NRAS are RAS-family oncogenes central to the MAPK signaling pathway; activating mutations drive uncontrolled proliferation and are among the most common oncogenic drivers across human cancers, with KRAS alone mutated in about 25% of all cancers.
RAS mutation status (KRAS or NRAS) determines eligibility for anti-EGFR antibody therapy (cetuximab, panitumumab) in metastatic colorectal cancer — any RAS mutation predicts lack of benefit and is a requirement to check before prescribing these drugs.
Detected via PCR-based mutation testing or NGS panel on tumor tissue; testing must cover the full range of clinically relevant RAS mutation sites (not just the single most common one) since any activating mutation in the RAS pathway confers anti-EGFR resistance.
A genuinely major, very recent development: the specific KRAS G12C mutation subtype now has its own targeted drugs — sotorasib and adagrasib — with adagrasib gaining FDA approval for colorectal cancer in 2024 (the first KRAS-targeting drug approved for this cancer type) and sotorasib following with a January 2025 approval in combination with panitumumab, both representing a major shift after RAS was considered "undruggable" for decades.
Sotorasib and adagrasib (2024-2025 approvals) represent a major breakthrough after RAS was long considered an undruggable target.
- FDA. (2025). FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer.
- MSKCC. (2024). FDA Approves First Colorectal Cancer Treatment that Targets G12C KRAS Gene.